

# Special Issue

## Advances in Pharmacomicrobiomics

### Message from the Guest Editor

Precision medicine aims to identify which drugs at which doses represent the best therapy for every single patient. Evidence is being accumulated that commensal microorganisms living in the human body may metabolize and/or accumulate intracellular drugs given to treat specific diseases, they may affect their clinical efficacy. In addition, these microorganisms may affect drug responses by interfering with drug pharmacodynamics. All of these effects may change interindividually and contribute to the variability in drug responses. The term pharmacomicrobiomics has been introduced to describe the contribution of microbiota to the variability in drug pharmacokinetics and pharmacodynamics. This Special Issue is intended to provide an updated overview on the recent progress in the field of pharmacomicrobiomics, also including strategies to modify the composition of microbiota to improve drug responses. Both original studies and review articles are welcomed for this Special Issue, which we hope will represent a stimulating forum for this new field of precision medicine.

### Guest Editor

Dr. Mauro Cataldi

Division of Pharmacology, Federico II University of Naples, Naples, Italy

### Deadline for manuscript submissions

closed (31 August 2023)



## Biomedicines

an Open Access Journal  
by MDPI

Impact Factor 3.9  
CiteScore 5.2  
Indexed in PubMed



[mdpi.com/si/121915](https://mdpi.com/si/121915)

*Biomedicines*

MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)

[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)





# Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 5.2  
Indexed in PubMed



[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)



## About the Journal

### Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

---

### Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPUS / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2024).